Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus paclitaxel/cisplatin neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2300068870Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Yanbian University
- Start
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, paclitaxel and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by The Affiliated Hospital of Yanbian University. Primary endpoints: Major pathological response and Pathological complete response. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxelcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300068870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068870.